Bone mineral density changes after 2 years of ARV treatment, compared to naive HIV-1-infected patients not on HAART. (Q41647237)

6 October 2017

Bone mineral density changes after 2 years of ARV treatment, compared to naive HIV-1-infected patients not on HAART. (English)

1 reference

6 October 2017

David Rey

1

1 reference

6 October 2017

Michele Treger

2

1 reference

6 October 2017

Jean Sibilia

3

1 reference

6 October 2017

Michele Priester

4

1 reference

6 October 2017

Claudine Bernard-Henry

5

1 reference

6 October 2017

Christine Cheneau

6

1 reference

6 October 2017

Rose-Marie Javier

7

1 reference

6 October 2017

26 November 2014

1 reference

Infectious diseases (London, England)

6 October 2017

1 reference

6 October 2017

47

1 reference

6 October 2017

2

1 reference

6 October 2017

88-95

1 reference

Prospective evaluation of bone markers, parathormone and 1,25-(OH)₂ vitamin D in HIV-positive patients after the initiation of tenofovir/emtricitabine with atazanavir/ritonavir or efavirenz

6 October 2017

1 reference

https://api.crossref.org/works/10.3109%2F00365548.2014.968610

Accelerated bone mineral loss in HIV-infected patients receiving potent antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365548.2014.968610

Reduced bone mineral density in human immunodeficiency virus-infected patients and its association with increased central adiposity and postload hyperglycemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365548.2014.968610

Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365548.2014.968610

Fractures after antiretroviral initiation

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365548.2014.968610

Bone disease in HIV infection: a practical review and recommendations for HIV care providers

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365548.2014.968610

Reduced bone mineral density in HIV-infected patients: prevalence and associated factors

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365548.2014.968610

Relationship between low bone mineral density and highly active antiretroviral therapy including protease inhibitors in HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365548.2014.968610

Evolution of bone mineral density in AIDS patients on treatment with zidovudine/lamivudine plus abacavir or lopinavir/ritonavir

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365548.2014.968610

Stable or increasing bone mineral density in HIV-infected patients treated with nelfinavir or indinavir

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365548.2014.968610

Comparison of changes in bone density and turnover with abacavir-lamivudine versus tenofovir-emtricitabine in HIV-infected adults: 48-week results from the ASSERT study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365548.2014.968610

Bone mineral density and fractures in antiretroviral-naive persons randomized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: Aids Clinical Trials Group A5224s, a substudy o

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365548.2014.968610

Longitudinal evolution of bone mineral density and bone markers in human immunodeficiency virus-infected individuals.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365548.2014.968610

Prevalence of causes of secondary osteoporosis and contribution to lower bone mineral density in HIV-infected patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365548.2014.968610

Low baseline CD4+ count is associated with greater bone mineral density loss after antiretroviral therapy initiation

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365548.2014.968610

Peak bone mass in young HIV-infected patients compared with healthy controls

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365548.2014.968610

HIV: inflammation and bone

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365548.2014.968610

Prevalence and risk factors of osteopenia/osteoporosis in Turkish HIV/AIDS patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365548.2014.968610

High prevalence of and progression to low bone mineral density in HIV-infected patients: a longitudinal cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365548.2014.968610

Changes in bone turnover and bone loss in HIV-infected patients changing treatment to tenofovir-emtricitabine or abacavir-lamivudine

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365548.2014.968610

Changes in bone mineral density over a 2-year period in HIV-1-infected men under combined antiretroviral therapy with osteopenia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365548.2014.968610

Bone mineral density in HIV participants randomized to raltegravir and lopinavir/ritonavir compared with standard second line therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365548.2014.968610

Bone turnover, osteoprotegerin/RANKL and inflammation with antiretroviral initiation: tenofovir versus non-tenofovir regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365548.2014.968610

Greater decrease in bone mineral density with protease inhibitor regimens compared with nonnucleoside reverse transcriptase inhibitor regimens in HIV-1 infected naive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365548.2014.968610

10.3109/00365548.2014.968610

21 January 2018

Identifiers

DOI

1 reference

6 October 2017

1 reference